Cargando…
Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography
This study aimed to assess the relationship between chosen antioxidants, namely selenoprotein P (SELENOP), peroxiredoxin-5 (Prdx-5), renalase and selected cardiovascular consequences tested in ambulatory blood pressure monitoring (ABPM) and echocardiography (ECHO). In our work, cardiovascular conseq...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295028/ https://www.ncbi.nlm.nih.gov/pubmed/37371917 http://dx.doi.org/10.3390/antiox12061187 |
_version_ | 1785063323072462848 |
---|---|
author | Czerwińska, Karolina Januszewska, Lidia Markiewicz-Górka, Iwona Jaremków, Aleksandra Martynowicz, Helena Pawlas, Krystyna Mazur, Grzegorz Poręba, Rafał Gać, Paweł |
author_facet | Czerwińska, Karolina Januszewska, Lidia Markiewicz-Górka, Iwona Jaremków, Aleksandra Martynowicz, Helena Pawlas, Krystyna Mazur, Grzegorz Poręba, Rafał Gać, Paweł |
author_sort | Czerwińska, Karolina |
collection | PubMed |
description | This study aimed to assess the relationship between chosen antioxidants, namely selenoprotein P (SELENOP), peroxiredoxin-5 (Prdx-5), renalase and selected cardiovascular consequences tested in ambulatory blood pressure monitoring (ABPM) and echocardiography (ECHO). In our work, cardiovascular consequences refer to higher mean blood pressure (MBP) and pulse pressure (PP) on ABPM, as well as to left atrial enlargement (LAE), left ventricular hypertrophy (LVH) and lower left ventricular ejection fraction (LVEF%) on ECHO. The study group consisted of 101 consecutive patients admitted to the Department of Internal Medicine, Occupational Diseases and Hypertension to verify the diagnosis of Obstructive Sleep Apnoea (OSA). Each patient underwent full polysomnography, blood tests, ABPM and ECHO. Both selenoprotein-P and renalase levels correlated with different ABPM and ECHO parameters. We found no correlation between the peroxiredoxin-5 level and none of the tested parameters. We point to the possible application of SELENOP plasma-level testing in the initial selection of high cardiovascular-risk patients, especially if access to more advanced examinations is limited. We further suggest SELENOP measurement as a possible indicator of patients at increased left ventricular hypertrophy risk who should be of particular interest and may benefit from ECHO testing. |
format | Online Article Text |
id | pubmed-10295028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102950282023-06-28 Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography Czerwińska, Karolina Januszewska, Lidia Markiewicz-Górka, Iwona Jaremków, Aleksandra Martynowicz, Helena Pawlas, Krystyna Mazur, Grzegorz Poręba, Rafał Gać, Paweł Antioxidants (Basel) Article This study aimed to assess the relationship between chosen antioxidants, namely selenoprotein P (SELENOP), peroxiredoxin-5 (Prdx-5), renalase and selected cardiovascular consequences tested in ambulatory blood pressure monitoring (ABPM) and echocardiography (ECHO). In our work, cardiovascular consequences refer to higher mean blood pressure (MBP) and pulse pressure (PP) on ABPM, as well as to left atrial enlargement (LAE), left ventricular hypertrophy (LVH) and lower left ventricular ejection fraction (LVEF%) on ECHO. The study group consisted of 101 consecutive patients admitted to the Department of Internal Medicine, Occupational Diseases and Hypertension to verify the diagnosis of Obstructive Sleep Apnoea (OSA). Each patient underwent full polysomnography, blood tests, ABPM and ECHO. Both selenoprotein-P and renalase levels correlated with different ABPM and ECHO parameters. We found no correlation between the peroxiredoxin-5 level and none of the tested parameters. We point to the possible application of SELENOP plasma-level testing in the initial selection of high cardiovascular-risk patients, especially if access to more advanced examinations is limited. We further suggest SELENOP measurement as a possible indicator of patients at increased left ventricular hypertrophy risk who should be of particular interest and may benefit from ECHO testing. MDPI 2023-05-30 /pmc/articles/PMC10295028/ /pubmed/37371917 http://dx.doi.org/10.3390/antiox12061187 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Czerwińska, Karolina Januszewska, Lidia Markiewicz-Górka, Iwona Jaremków, Aleksandra Martynowicz, Helena Pawlas, Krystyna Mazur, Grzegorz Poręba, Rafał Gać, Paweł Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title | Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title_full | Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title_fullStr | Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title_full_unstemmed | Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title_short | Selenoprotein P, Peroxiredoxin-5, Renalase and Selected Cardiovascular Consequences Tested in Ambulatory Blood Pressure Monitoring and Echocardiography |
title_sort | selenoprotein p, peroxiredoxin-5, renalase and selected cardiovascular consequences tested in ambulatory blood pressure monitoring and echocardiography |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295028/ https://www.ncbi.nlm.nih.gov/pubmed/37371917 http://dx.doi.org/10.3390/antiox12061187 |
work_keys_str_mv | AT czerwinskakarolina selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT januszewskalidia selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT markiewiczgorkaiwona selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT jaremkowaleksandra selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT martynowiczhelena selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT pawlaskrystyna selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT mazurgrzegorz selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT porebarafał selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography AT gacpaweł selenoproteinpperoxiredoxin5renalaseandselectedcardiovascularconsequencestestedinambulatorybloodpressuremonitoringandechocardiography |